Research
Hormonal
Use of GLP-1 receptor agonists (GLP-1 RAs) is associated with an increased risk of gallbladder or biliary diseases (RR, 1.37; 95% CI, 1.23-1.52).
Healthcare providers should be aware of the potential increased risk of gallbladder diseases when prescribing GLP-1 RAs.
StrongSupportsmedium confidence
Among all included trials, randomization to GLP-1 RA treatment was associated with increased risks of gallbladder or biliary diseases (RR, 1.37; 95% CI, 1.23-1.52).
Why this rating
Based on a systematic review and meta-analysis of randomized clinical trials.
Source
Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
Liyun He et al. · JAMA Internal Medicine · 2022
DOI 10.1001/jamainternmed.2022.0338
Meta-analysisCited 285×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 RA use is associated with a higher risk of gallbladder or biliary diseases at higher doses (RR, 1.56; 95% CI, 1.36-1.78) compared to lower doses (RR, 0.99; 95% CI, 0.73-1.33).Strong
- GLP-1 RA use is associated with increased risk of gallbladder or biliary diseases for longer durations (RR, 1.40; 95% CI, 1.26-1.56) compared to shorter durations (RR, 0.79; 95% CI, 0.48-1.31).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →